Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C15H11I2O3.Na |
| Molecular Weight | 516.0447 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].OC1=C(I)C=C(CC(C([O-])=O)C2=CC=CC=C2)C=C1I
InChI
InChIKey=JFFBJAOFKRCWPX-UHFFFAOYSA-M
InChI=1S/C15H12I2O3.Na/c16-12-7-9(8-13(17)14(12)18)6-11(15(19)20)10-4-2-1-3-5-10;/h1-5,7-8,11,18H,6H2,(H,19,20);/q;+1/p-1
Iodoalphionic acid is the contrast medium, which was used for gallbladder examination. It is rarely appeared in the colon and, therefore, rarely masked the gallbladder. The density of the shadow produced by Iodoalphionic acid was greater than that produced by iodophthalein. It was reliable peroral cholecystographic medium, which was less objectionable to take and seldom causes vomiting. Diarrhoea occurred in some cases, but not more often than with tetraiodophenolphthalein. The ingestion of Iodoalphionic acid resulted in low thyroidal radioiodine accumulation for periods ranging from a few weeks to many months.
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
4.2 g single, oral Studied dose |
unhealthy, UNKNOWN Health Status: unhealthy Age Group: UNKNOWN Sex: unknown Sources: |
Other AEs: Unpleasant taste, Nausea... Other AEs: Unpleasant taste (16 patients) Sources: Nausea (10 patients) Vomiting (2 patients) Diarrhea (3 patients) pain on micturition (5 patients) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Nausea | 10 patients | 4.2 g single, oral Studied dose |
unhealthy, UNKNOWN Health Status: unhealthy Age Group: UNKNOWN Sex: unknown Sources: |
| Unpleasant taste | 16 patients | 4.2 g single, oral Studied dose |
unhealthy, UNKNOWN Health Status: unhealthy Age Group: UNKNOWN Sex: unknown Sources: |
| Vomiting | 2 patients | 4.2 g single, oral Studied dose |
unhealthy, UNKNOWN Health Status: unhealthy Age Group: UNKNOWN Sex: unknown Sources: |
| Diarrhea | 3 patients | 4.2 g single, oral Studied dose |
unhealthy, UNKNOWN Health Status: unhealthy Age Group: UNKNOWN Sex: unknown Sources: |
| pain on micturition | 5 patients | 4.2 g single, oral Studied dose |
unhealthy, UNKNOWN Health Status: unhealthy Age Group: UNKNOWN Sex: unknown Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 9.0 |
inconclusive [IC50 17.3768 uM] | |||
Page: 11.0 |
inconclusive [IC50 38.9018 uM] | |||
Page: 51.0 |
no | |||
Page: 104.0 |
no | |||
Page: 93.0 |
no | |||
Page: 10.0 |
yes [IC50 24.5454 uM] | |||
Page: 5.0 |
yes [IC50 9.7717 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 93 | 95 |
no |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 103.0 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening. | 2004-05-06 |
|
| [Competitive interrelations between bilirubin and x-ray contrast agents in binding with human serum albumin]. | 1986-03-01 |
|
| [Effect of tri-iodine-containing x-ray contrast substances on the blood coagulation system in an experiment]. | 1984-07-01 |
|
| [Effect of contrast agents on the iodine-absorbing function of the thyroid gland]. | 1982-03-01 |
|
| Unaltered bromsulphalein retention following cholecystography. | 1968-10 |
|
| [A new mercurometric determination of pheniodol (Coletrast)]. | 1967-08 |
|
| Influence of iodoalphionic acid priodax, with and without thyrotropin, on thyroidal I 131 uptake in euthyroid patients. | 1957-01 |
|
| Effects of an organic iodine compound priodax on tests of thyroid function. | 1957-01 |
|
| Cholegraphy; the new contrast medium biligrafin. | 1955-05 |
|
| [Duodenal intubation of acranil and iodoalphionic acid in therapy of teniasis]. | 1954-01-01 |
|
| [Comparative study of iodopanoic acid (telepaque) and iodoalphionic acid (pheniodol) in cholecystography; densitometric and plainimetric x-ray study of 100 cases]. | 1954 |
|
| A comparative clinical study of priodax and telepague, including 1,000 examinations. | 1953-02 |
|
| [Comparative cholecystographic study of iodopanoic acid (telepaque) and iodoalphionic acid]. | 1953 |
|
| [Inefficacy of iodoalphionic acid in radical cure of taeniasis]. | 1952-11-01 |
|
| Pseudo-albuminuria following monophen and priodax. | 1952-09 |
|
| Comparison of cholecystography with iodoalphionic acid (priodax) and a new gallbladder dye, iodopropanoic acid (telepaque). | 1952-08 |
|
| Absorption and excretion of pheniodol. | 1951-07-21 |
|
| Absorption and excretion of pheniodol labelled with radioactive iodine. | 1951-04 |
|
| Priodax and pseudoalbuminuria. | 1950-11 |
|
| The compatibility of castor oil and priodax in concurrent examination of the colon and gallbladder. | 1949-07 |
|
| Some experiences with priodax. | 1946-06 |
|
| Pheniodol, a new dye for cholecystography. | 1946-02 |
|
| Pheniodol: A Contrast Medium for Cholecystography. | 1943-11-27 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20785145
4.2 g. suspended in water or milk
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL83906
Created by
admin on Mon Mar 31 18:09:09 GMT 2025 , Edited by admin on Mon Mar 31 18:09:09 GMT 2025
|
PRIMARY | |||
|
3303
Created by
admin on Mon Mar 31 18:09:09 GMT 2025 , Edited by admin on Mon Mar 31 18:09:09 GMT 2025
|
PRIMARY | |||
|
C175842
Created by
admin on Mon Mar 31 18:09:09 GMT 2025 , Edited by admin on Mon Mar 31 18:09:09 GMT 2025
|
PRIMARY | |||
|
23665871
Created by
admin on Mon Mar 31 18:09:09 GMT 2025 , Edited by admin on Mon Mar 31 18:09:09 GMT 2025
|
PRIMARY | |||
|
D3N32O7NLB
Created by
admin on Mon Mar 31 18:09:09 GMT 2025 , Edited by admin on Mon Mar 31 18:09:09 GMT 2025
|
PRIMARY | |||
|
100000082236
Created by
admin on Mon Mar 31 18:09:09 GMT 2025 , Edited by admin on Mon Mar 31 18:09:09 GMT 2025
|
PRIMARY | |||
|
SUB09766MIG
Created by
admin on Mon Mar 31 18:09:09 GMT 2025 , Edited by admin on Mon Mar 31 18:09:09 GMT 2025
|
PRIMARY | |||
|
230-288-5
Created by
admin on Mon Mar 31 18:09:09 GMT 2025 , Edited by admin on Mon Mar 31 18:09:09 GMT 2025
|
PRIMARY | |||
|
4171
Created by
admin on Mon Mar 31 18:09:09 GMT 2025 , Edited by admin on Mon Mar 31 18:09:09 GMT 2025
|
PRIMARY | |||
|
7009-60-1
Created by
admin on Mon Mar 31 18:09:09 GMT 2025 , Edited by admin on Mon Mar 31 18:09:09 GMT 2025
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD